Psychedelic Stocks Archives - Page 6 of 61

ThursdaySep 19, 2024 10:00 am

Ancient Psychedelics History and What We Can Learn from It

Interest in psychedelics from the Western world has been growing in the recent years, as more studies uncover the mental-health benefits of psychedelics such as psilocybin, LSD and MDMA. While this field continues to grow, discoveries are also shedding light on the role that these substances played in ancient societies. Dr.Yuria Celidwen, a senior academic at UC Berkeley, reveals that the term “psychedelic” is modern. For centuries, Indigenous communities referred to these drugs as spirit medicines. Historical documents show the use of these substances for healing was a minor role, with major uses being sacred rituals, palliative care, strengthening connections…

TuesdaySep 17, 2024 10:00 am

Federal Officials Admit Psychedelic Therapy Could Treat PTSD, Call for Additional Research

Last week, representatives of various federal agencies met to discuss new treatments for post-traumatic stress disorder (PTSD), including psychedelics. Speakers at the event included representatives from the Veterans Affairs department, Substance Abuse and Mental Health Services Administration, the U.S. Food and Drug Administration (FDA), the U.S. Department of Health and Human Services and the U.S. Department of Defense. The event was hosted by the Reagan-Udall Foundation for the FDA. While it didn’t center on psychedelic-assisted treatments only, many exchanged views on the topic. During the discussion, those attending acknowledged the potential of psychedelics in treating post-traumatic stress disorder and highlighted…

ThursdaySep 12, 2024 10:00 am

Study Suggests Psychedelics Generally Well Tolerated

New research has determined that classic psychedelics including psilocybin and LSD are well tolerated in research and clinical settings, with rare adverse events occurring. For their study, the researchers focused on evaluating the severity, frequency and nature of adverse events linked to psilocybin, LSD, 5-MeO-DMT and DMT. The researchers carried out a meta-analysis and systematic review that studied data obtained from 114 studies that involved more than 3,500 participants. The studies included were drawn from different databases, including Web of Science, PsycINFO, MEDLINE, and Scopus. The research covered studies published up to Feb. 8, 2024. They also had two independent…

TuesdaySep 10, 2024 10:00 am

Authors of New Study Recommend Shift from Mystical Experiences in Psychedelic Research

Interest in psychedelics has increased significantly these last few years, with researchers finding out more about the potential mental health benefits of substances such as LSD, mescaline, DMT and psilocybin. Thus far, research has determined that these drugs induce intense emotional experiences and alter individuals’ perception and cognition, with some also causing mystical experiences. Now, a recently conducted review has found that the therapeutic potential of these substances extends beyond mystical experiences. The study authors argued that psychedelic benefits weren’t universal, noting that the drugs could also induce existential crises, anxiety and depersonalization. In their review, they highlight the importance…

ThursdaySep 05, 2024 10:00 am

New Research Suggests Psychedelics Have Proven Potential in Alcoholism, Drug-Addiction Treatment

Recently conducted research may have found new approaches to treat alcohol-use disorder. One study determined that administering psilocybin is both effective and safe in decreasing the consumption of alcohol in patients with alcohol-use disorder. This study examined 10 adults with severe alcohol use disorder during the 12-week research period. For their open-label study, investigators at the University of Copenhagen administered one 25mg psilocybin dose to each participant. They observed that the consumption of alcohol by participants reduced significantly, with most of them consuming fewer drinks and craving alcohol less following the treatment. In their report, the researchers explained that the…

TuesdaySep 03, 2024 10:00 am

Psychedelics Trigger Brain Plasticity in Addiction Treatment

Psychedelics are a class of drugs that induce different states of consciousness, with classic psychedelics such as mescaline, psilocybin, DMT and LSD acting as agonists of the 5-HT2A serotonin receptor. Over the last 20 years, we have observed a significant resurgence of studies focused on the use of psychedelics to address beliefs, traumas and behavioral patterns underlying mental-health disorders. Various studies have centered on re-evaluating the therapeutic potential of psychedelics, including MDMA, ketamine and psilocybin, in treating addiction. Thus far, the studies have demonstrated that psychedelics may be effective, particularly where traditional treatments fall short. Some studies have determined that…

ThursdayAug 29, 2024 10:00 am

Study Suggests Efficacy of Psychedelics Exaggerated by Scientists

In the last couple of years, we have seen interest in psychedelic treatments increase significantly as more studies unearth the benefit of the substances, particularly for mental-health conditions. Randomized controlled trials have found that psychedelics such as LSD, psilocybin, and ayahuasca may offer considerable relief from symptoms of depression. While trials have proven the drugs’ effectiveness in treating mental-health conditions, the mechanisms by which these substances work as well as their actual effectiveness remains unknown. This is a significant concern in this field, especially since conducting successful blind clinical trials is rather difficult. Blinding is necessary in trials because it…

TuesdayAug 27, 2024 10:00 am

MDMA Rejection Raises New Questions on Psychedelic Drug Clinical Trials

The U.S. Food and Drug Administration (FDA) recently rejected an application to approve the use of MDMA as a treatment for post-traumatic stress disorder (PTSD). The MDMA formulation, developed by Lykos Therapeutics, would have been administered in combination with psychotherapy if it had been approved. In its rejection, the federal agency requested for more clinical trials to be done to gather additional data on the drug’s effectiveness and safety. This decision comes just months after the FDA’s advisory committee determined that the application made by Lykos was lacking on both fronts. The decision is a significant change in the drug’s…

ThursdayAug 22, 2024 10:00 am

Study Suggests Psilocybin Triggers Mechanisms for Inner Healing within Depression Patients

Psychedelics are known to alter an individual’s mood, perception and cognitive processes when ingested. These substances can also alter one’s perception of time, induce hallucinations, and lead to deep introspective and emotional experiences. Individuals who use psychedelics have reported that the drugs may facilitate inner healing through promoting introspection and emotional release. The drugs can also help alleviate feelings of depression and isolation by creating a feeling of unity and interconnectedness. Now new research has looked into whether psilocybin can prompt inner healing for patients with depression. The research is based on a hypothesis that people who consume a high…

TuesdayAug 20, 2024 2:15 pm

FDA’s Rejection of MDMA Therapy Draws Ire of Psychedelics Experts

Last week, the U.S. Food and Drug Administration (FDA) rejected a new drug application for MDMA to be administered as treatment for post-traumatic stress disorder. In its rejection, the federal agency asked the company that filed the application, Lykos Therapeutics, to conduct additional trials to further study the effectiveness and safety of its psychedelic formulation. This would require additional funding as well as a number of years to complete, which doesn’t align with Lykos Therapeutics’ expectations. The FDA’s ruling left many upset, particularly experts and patient advocates involved in the development and research of psychedelic treatments. One neuroscientist at the…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Psychedelic Stocks